Nexalis plots capital raise as search goes on for new funding partner

Cannabinoid drug development firm Nexalis Therapeutics is planning a capital raise to relieve the pressure on its finances as it continues to seek funds to continue its clinical trial program.

The firm, which lost a $52 million funding facility in May, said the “timing and structure” of the raise has not been finalised but claimed it is likely to be “successful”.